GentiBio, Inc., a Boston, MA-based biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for immunology, closed a $157m Series A financing.
The round was led by Matrix Capital Management with participation from Avidity Partners, JDRF T1D Fund, OrbiMed, RA Capital Management, and Novartis Venture Fund, and Seattle Children’s Research Institute.
The company intends to use the funds to advance its potential functional cure for Type 1 Diabetes (T1D) to the clinic alongside multiple other pipeline programs in chronic autoimmunity and autoinflammation.
Led by Adel Nada, M.D., M.S., President and Chief Executive Officer, GentiBio is a biotherapeutics company advancing engineered regulatory T cells programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. Its proprietary autologous and allogeneic engineered Tregs platform integrates key complementary technologies needed to (re)establish immune tolerance and overcome major limitations in existing regulatory T cell therapeutics.
GentiBio is currently selecting its clinical candidate for T1D and will begin IND-enabling studies before the end of the year.
The company launched in August 2020 with $20m seed funding from OrbiMed, Novartis Venture Fund and RA Capital.